Mobile

A phase III, randomized, observer blind, multi-centre study to evaluate the immunogenicity, safety and reactogenicity of study vaccine GSK1557482A (FluLaval thiomersal-free), Fluarix and FluLaval thio...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-001445-26

A phase III, randomized, observer blind, multi-centre study to evaluate the immunogenicity, safety and reactogenicity of study vaccine GSK1557482A (FluLaval thiomersal-free), Fluarix and FluLaval thiomersal-containing vaccines in young adult (18 to 60 years) and elderly subjects (over 60 years)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• To evaluate the humoral immune response (anti-haemagglutinin antibodies) against each vaccine strain 21 days after vaccination with FluLaval thiomersal-free, FluLaval thiomersal-containing and Fluarix vaccines in adult (18-60 years) and elderly (over 60 years) subjects. • To assess during the active phase study period (30 days) the safety and reactogenicity of FluLaval thiomersal-free, FluLaval thiomersal-containing and Fluarix vaccines.

Critère d'inclusion

  • Immunization against influenza of healthy adults

Liens